Miller Anestesia

248. Gallant EM, Foldes FF, Rempel WE, Gronert GA:

Verapamil is not a therapeutic adjunct to dantro-

lene in porcine malignant hyperthermia. Anesth

Analg 64:601-606, 1985.

249. Harrison GG,Wright IG, Morrell DF: The effects of

calcium channel blocking drugs on halothane ini-

tiation of malignant hyperthermia in MHS swine

and on the established syndrome.Anaesth Intensive

Care 16:197-201, 1988.

250. McGraw TT, Keon TP: Malignant hyperthermia

and the clean machine. Can J Anaesth 36:530-532,

1989.

251. Schonell LH, Sims C, Bulsara M: Preparing a new

generation anaesthetic machine for patients suscep-

tible to malignant hyperthermia. Anaesth Intensive

Care 31:58-62, 2003.

252. Anetseder M, Hager M, Müller-Reible C, Roewer N:

Regional lactate and carbon dioxide concentrations

in a metabolic test for malignant hyperthermia.

Lancet 362:494, discussion 494-495, 2003.

253. Bina S, Cowan G, Karaian J, et al: Effects of caffeine,

halothane,and 4-chloro-

-cresol on skeletal muscle

lactate and pyruvate in malignant hyperthermia–

susceptible and normal swine as assessed by micro-

dialysis. Anesthesiology 104:90-100, 2006.

254. Bina S, Muldoon S, Bunger R: Effects of ryanodine

on skeletal muscle lactate and pyruvate in malig-

nant hyperthermia–susceptible and normal swine

as assessed by microdialysis. Eur J Anaesthesiol

25:48-57, 2008.

255. Schuster F, Metterlein T, Kranke P, et al: Intramus-

cular injection of sevoflurane detects malignant

hyperthermia predisposition in susceptible pigs.

Anesthesiology 107:616-620, 2007.

256. SchusterF,SchöllH,HagerM

,etal:Thedose-response

relationship and regional distribution of lactate after

intramuscular injection of halothane and caffeine in

malignant hyperthermia–susceptible pigs. Anesth

Analg 102:468-472, 2006.

257. GirardT,CavagnaD,PadovanE

,etal:B-lymphocytes

from malignant hyperthermia–susceptible patients

have an increased sensitivity to skeletal muscle

ryanodine receptor activators. J Biol Chem

276:48077-48082, 2001.

258. Litman RS, Rosenberg H: Malignant hyperthermia:

Update on susceptibility testing. JAMA 293:2918-

2924, 2005.

259. McKinney LC, Butler T, Mullen SP, Klein SG: Cha-

racterization of ryanodine receptor–mediated

calcium release in human B cells: Relevance to diag-

nostic testing for malignant hyperthermia.Anesthe-

siology 104:1191-1201, 2006.

260. Ording H,Foder B,Scharff O: Cytosolic free calcium

concentrations in lymphocytes from malignant

hyperthermia susceptible patients. Br J Anaesth

64:341-345, 1990.

261. Sei Y, Brandom BW, Bina S, et al: Patients with

malignant hyperthermia demonstrate an altered

calcium control mechanism in B lymphocytes.

Anesthesiology 97:1052-1058, 2002.

262. Gareau PJ, Janzen EG, Towner RA, Stewart WA: In

vivo

P NMR spectroscopy studies of halothane

induced porcine stress syndrome. No effect of

C-phenyl N-tert-butyl nitrone (PBN). Free Radic

Res Commun 19:43-50, 1993.

263. Payen JF, Bosson JL, Bourdon L, et al: Improved

noninvasive diagnostic testing for malignant hyper-

thermia susceptibility from a combination of meta-

bolites determined in vivo with

P-magnetic

resonance spectroscopy. Anesthesiology 78:848-

855, 1993.

Trastornos neuromusculares e hipertermia maligna

961

Sección

III

Control de la anestesia